Purpose of Review
Narcolepsy is a chronic, disabling neurologic disorder characterized by excessive daytime sleepiness (EDS) and in up to 60% of patients, cataplexy. Currently, new treatments with varying mechanisms of action have recently been approved or are in clinical development. This review aims to summarize the progress to date on this information on these agents.
Over the last decade, researchers have made great strides in understanding the biology of narcolepsy. The discovery of ORX deficiency in NT1 opened new therapeutic options oriented towards ORX-based therapies, especially nonpeptide ORX receptor agonists that are currently under development. These agents include novel oxybate formulations (once-nightly [FT218]; low sodium [JZP-258]), a selective norepinephrine-reuptake inhibitor (AXS-12), and a product combining modafinil and an astroglial connexin inhibitor (THN102).
Novel treatments in narcolepsy may provide further patient-oriented individualized treatment. Further developments could conceivably be used for development of further novel therapeutic options.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Papers of particular interest, published recently, have been highlighted as: • Of importance
Scheer D, Schwartz SW, Parr M, Zgibor J, Sanchez-Anguiano A, Rajaram L. Prevalence and incidence of narcolepsy in a US health care claims database, 2008–2010. Sleep. 2019;42(7):zsz091. https://doi.org/10.1093/sleep/zsz091.
Gélineau J, De La Narcolepsie, Gazette des Hôpitaux Civils et Militaires 1880; part a, 53: 626–628, part b,635–637.
Silber MH, Krahn LE, Olson EJ, Pankratz VS. The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Sleep. 2002;25(2):197–202.
Longstreth WT Jr, Koepsell TD, Ton TG, Hendrickson AF, van Belle G. The epidemiology of narcolepsy. Sleep. 2007;30(1):13–26. https://doi.org/10.1093/sleep/30.1.13.
• Szabo ST, Thorpy MJ, Mayer G, Peever JH, Kilduff TS. Neurobiological and immunogenetic aspects of narcolepsy: implications for pharmacotherapy. Sleep Med Rev. 2019;43:23–36 Dr. M Thorpy is a leader in pharmacotherapeutics as regards narcolepsy. This article reviewed treatment agents based on the neurobiology profiles particularly regulation of locus coeruleus (LC) norepinephrine (NE) neuron activity which appears to be central to the therapeutic ability of these agents.
Dauvilliers Y, Siegel JM, Lopez R, Torontali ZA, Peever JH. Cataplexy–clinical aspects, pathophysiology and management strategy. Nat Rev Neurol. 2014;10(7):386–95.
Morgenthaler TI, Kapur VK, Brown T, Swick TJ, Alessi C, Aurora RN, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin [published correction appears in Sleep. 2008 Feb 1;31(2): table of contents]. Sleep. 2007;30(12):1705–11. https://doi.org/10.1093/sleep/30.12.1705.
American Academy of Sleep Medicine. International classification of sleep disorders. 3. Darien: American Academy of Sleep Medicine; 2014.
Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000;355:39–40.
Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med. 2000;6:991–7.
Pizza F, Jaussent I, Lopez R, Pesenti C, Plazzi G, Drouot X, et al. Car crashes and central disorders of hypersomnolence: a French study. PLoS One. 2015;10:e0129386.
Bayard S, Croisier Langenier M, De C, Cock V, et al. Executive control of attention in narcolepsy. PLoS One. 2012;7:e33525.
Kornum BR, Knudsen S, Ollila HM, Pizza F, Jennum PJ, Dauvilliers Y, et al. Narcolepsy. Nat Rev Dis Prim. 2017;3:16100.
Thorpy MJ, Dauvilliers Y. Clinical and practical considerations in the pharmacologic management of narcolepsy. Sleep Med. 2015;16:9–18.
Rasmussen N. Making the first anti-depressant: amphetamine in American medicine, 1929–1950. J Hist Med Allied Sci. 2006;61(3):288–323.
Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet. 2007;369:499–511.
Barateau L, Lopez R, Dauvilliers Y. Treatment options for narcolepsy. CNS Drugs. 2016;30:369–79.
Duchêne A, Perier M, Zhao Y, Liu X, Thomasson J, Chauveau F, et al. Impact of astroglial connexins on modafinil pharmacological properties. Sleep. 2016;39:1283–92.
Roth T, Dauvilliers Y, Guinta D, et al. Effect of sodium oxybate on disrupted nighttime sleep in patients with narcolepsy. J Sleep Res. 2016;26:407–14.
Bogan RK, Roth T, Schwartz J, Miloslavsky M. Time to response with sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy. J Clin Sleep Med. 2015;11:427–32.
Wang J, Greenberg H. Status cataplecticus precipitated by abrupt withdrawal of venlafaxine. J Clin Sleep Med. 2013;9(7):715–6. Published 2013 Jul 15. https://doi.org/10.5664/jcsm.2848.
Bosco A, Lopez R, Barateau L, et al. Effect of psychostimulants on blood pressure profile and endothelial function in narcolepsy. Neurology. 2018:10–1212.
Barateau L, Liblau R, Peyron C, et al. Narcolepsy type 1 as an autoimmune disorder: evidence, and implications for pharmacological treatment. CNS Drugs. 2017;31:821–34.
Dauvilliers Y, Bassetti C, Lammers GJ, Arnulf I, Mayer G, Rodenbeck A, et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013;12:1068–75.
Dauvilliers Y, Arnulf I, Szakacs Z, et al. Long-term use of pitolisant to treat patients with narcolepsy: harmony III study. Sleep. 2019;42:zsz174.
Szakacs Z, Dauvilliers Y, Mikhaylov V, Poverennova I, Krylov S, Jankovic S, et al. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:200–7.
Thorpy MJ, Shapiro C, Mayer G, Corser BC, Emsellem H, Plazzi G, et al. A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Ann Neurol. 2019;85:359–70.
Strollo PJ Jr, Hedner J, Collop N, Lorch DG Jr, Chen D, Carter LP, et al. Solriamfetol for the treatment of excessive sleepiness in OSA: a placebo-controlled randomized withdrawal study. Chest. 2019;155:364–74.
JZP 258 [drug profile]: Adis Insight 2019. https://adisinsight.springer.com/drugs/800048256. Accessed 26 Apr 2020.
Jazz Pharmaceuticals announces positive top-line results from phase 3 study of JZP-258 in adult narcolepsy patients with cataplexy and excessive daytime sleepiness [press release]. 2019. https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-positive-top-line-results-phase-3. Accessed 20 Mar 2020.
Bogan R, Thorpy M, Dauvilliers Y, Del Rio Villegas R, Foldvary-Schaefer N, Skowronski R, et al. Efficacy and safety of JZP-258 in a phase 3 double-blind, placebo-controlled, randomized-withdrawal study in adults with narcolepsy with cataplexy [abstract]. Biennial World Sleep Congress; 20–25 2019; Vancouver.
Sodium oxybate controlled release—Avadel Pharmaceuticals [drug profile]. Adis Insight; 2018. https://adisinsight.springer.com/drugs/800041142. Accessed 27 Nov 2019.
Sodium oxybate for treatment of excessive daytime sleepiness and cataplexy in narcolepsy [ClinicalTrials.gov identifier NCT02720744]. National Institutes of Health, ClinicalTrials.gov. 2019.https://clinicaltrials.gov/ct2/show/NCT02720744. Accessed 29 Apr 2020.
A study to compare the absorption into the body of the drug sodium oxybate in FT218 in comparison to the currently marketed product Xyrem® [EudraCT2016-004342-28]. 2017 Oct 17. https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004342-28/NL. Accessed 20 Apr 2020.
Axsome announces AXS-12 for narcolepsy [press release]. 2018. https://axsometherapeuticsinc.gcs-web.com/static-files/fa862bca-7be0-4849-9f00-68894655ab86. Accessed 6 Apr 2020.
Axsome Therapeutics receives FDA orphan drug designation for AXS-12 for the treatment of narcolepsy [press release]. 2018. https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-receives-fda-orphan-drug-designation-axs-12?field_nir_news_date_value%5bmin%5d=2019. Accessed 3 Apr 2020.
Larrosa O, de la Llave Y, Bario S, Granizo JJ, Garcia-Borreguero D. Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study. Sleep. 2001;24(3):282–5.
Theranexus announces preliminary results of phase II trial of THN102 on narcolepsy patients [press release]. 2019. https://www.theranexus.com/images/pdf/Theranexus_PR_result_narcolepsy_20199227_VDEF.pdf. Accessed 24 Apr 2020.
Duchene A, Perier M, Zhao Y, Liu X, Thomasson J, Chauveau F, et al. Impact of astroglial connexins on modafinil pharmacological properties. Sleep. 2016;39(6):1283–92.
Safety and efficacy of THN102 on sleepiness in narcoleptic patients [ClinicalTrials.gov identifier NCT02821715]. National Institutes of Health, ClinicalTrials.gov. 2018. https://clinicaltrials.gov/ct2/show/NCT02821715. Accessed 24 Apr 2020.
Theranexus provides 2018 full-year results and update on activities [press release]. 2019. https://www.actusnews.com/en/THERANEXUS/pr/2019/04/17/theranexus-provides-2018-full-year-results-and-update-on-activities. Accessed 02 Apr 2020.
Ramakrishna N, Gopinadh B, Renny A, Ramkumar S, Kumar GV, Kumar PS, et al. A potent and selective histamine H3 receptor inverse agonist - phase-2 investigational new drug for the treatment of narcolepsy - differentiating factors with competitor clinical candidates. Sleep. 2019;42(Supplement_1):A57.
Vijay B, Saivishal D, Chaitanya T, Ramkumar S, Surendra P, Rajesh B, et al. a histamine H3 receptor inverse agonist produces wake promoting effect in orexin-2-saporin lesioned rats. Sleep. 2019;42(Supplement_1):A22–3.
Takenoshita S, Sakai N, Chiba Y, Matsumura M, Yamaguchi M, Nishino S. An overview of hypocretin based therapy in narcolepsy. Expert Opin Investig Drugs. 2018;27(4):389–406.
• Barateau L, Dauvilliers Y. Recent advances in treatment for narcolepsy. Ther Adv Neurol Disord. 2019;12:1–12 This was one of the very few reviews which highlighted the role of a precise medicine approach for treatment for narcolepsy based on the clinical and biological profiles.
Evans R, Tanaka S, Tanaka S, Touno S, Shimizu K, Sakui S, et al. A phase 1 single ascending dose study of a novel orexin 2 receptor agonist, TAK-925, in healthy volunteers (HV) and subjects with narcolepsy type 1 (NT1) to assess safety, tolerability, pharmacokinetics, and pharmacodynamic outcomes [oral presentation]. World Sleep Congress; 20–25 2019; Vancouver.
Barateau L, Liblau R, Peyron C, Dauvilliers Y. Narcolepsy type 1 as an autoimmune disorder: evidence, and implications for pharmacological treatment. CNS Drugs. 2017;31(10):821–34.
Conflict of Interest
The authors declare no conflicts of interest in preparing this article.
Human and Animal Rights
This article does not contain any studies with human or animal subjects performed by any of the authors.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Insomnia and Psychotherapy
About this article
Cite this article
Akpa, B., Lee, K. Update on Novel Medications to Treat Narcolepsy. Curr Sleep Medicine Rep 6, 189–197 (2020). https://doi.org/10.1007/s40675-020-00178-8
- Hypocretin, orexin
- Sodium oxybate